Novo Nordisk has appointed Jamey Millar, former CEO of Optum Specialty Holdings, as the drug company’s executive vice president of U.S. operations, effective Feb. 5.
In the role, Mr. Millar will oversee Novo Nordisk’s largest sales region, according to Novo Nordisk. The Denmark-based company, which is one of the world’s leading GLP-1 drug manufacturers, announced the executive management change Feb. 3 in its 2025 financial report.
Since 2021, Mr. Millar has served UnitedHealth Group’s OptumRx and Optum Specialty Holdings. Prior to those roles, he worked for GSK and Procter & Gamble for over 20 years, collectively.
The previous executive vice president of U.S. operations, Dave Moore, “decided to leave Novo Nordisk for personal reasons,” Novo Nordisk said.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
